Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0140-6736(82)90175-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical Presentation and Neuro-Ophthalmological Features in Spinocerebellar Ataxia Type 3: A Case Report and Literature Review.
J Neuroophthalmol
May 2024
Bascom Palmer Eye Institute (AK, RER-L), University of Miami, Miami, Florida; and New England Eye Center (EL, LNV, TRH, YM-P), Tufts University Medical Center, Boston, Massachusetts.
Rovatirelin ameliorates motor dysfunction in the cytosine arabinoside-induced rat model of spinocerebellar degeneration via acetylcholine and dopamine neurotransmission.
Clin Exp Pharmacol Physiol
September 2022
Central Research Laboratories, Kissei Pharmaceutical Co., Ltd., Azumino, Nagano, Japan.
Thyrotropin-releasing hormone (TRH) and the TRH mimetic taltirelin have been used in Japan for the treatment of spinocerebellar degeneration (SCD), a type of progressive ataxia. A TRH mimetic, rovatirelin, ameliorates ataxia symptoms in the rolling mouse Nagoya, a hereditary SCD model. The aim of this study was to verify the effects of oral administration of rovatirelin on a cytosine arabinoside (Ara-C)-induced ataxia rat model, a sporadic SCD model characterized by gait abnormalities and falls because of cerebellar atrophy and investigate the central nervous system mechanism associated with rovatirelin-mediated amelioration of motor dysfunction in these rats.
View Article and Find Full Text PDFAmeliorating effect of rovatirelin on the ataxia in rolling mouse Nagoya.
Eur J Pharmacol
September 2020
Central Research Laboratories, Kissei Pharmaceutical Co, Ltd., 4365-1, Hotaka Kashiwabara, Azumino Nagano, 399-8304, Japan. Electronic address:
Rovatirelin is a newly synthetized thyrotropin-releasing hormone (TRH) analog. This study aimed to investigate the effect of rovatirelin on motor function using rolling mouse Nagoya (RMN), a mouse model of hereditary ataxia, and compare it with that of taltirelin, which is clinically used to treat spinocerebellar degeneration in Japan. We also examined the effect of rovatirelin on glucose metabolism in various brain regions of RMN using autoradiography (ARG).
View Article and Find Full Text PDFDifferential effects of thyrotropin releasing hormone (TRH) on motor execution and motor adaptation process in patients with spinocerebellar degeneration.
J Neurol Sci
August 2020
Division of Neurology, Department of Brain and Neurosciences, Faculty of Medicine, Tottori University, Yonago, Japan; Department of Neurology, Kitasato University School of Medicine, Sagamihara, Japan.
Background: The cerebellum is known to play a crucial role in sensori-motor adaptation, which includes the prism adaptation. TRH has been widely used as a treatment for cerebellar ataxia in Japan, however effects of TRH on cerebellar adaptation process have not been studied. Here, we studied effects of TRH treatment on the prism adaptation task.
View Article and Find Full Text PDFThe forgotten effects of thyrotropin-releasing hormone: Metabolic functions and medical applications.
Front Neuroendocrinol
January 2019
Internal Medicine (Dept. of Endocrinology and Diabetology, Angiology, Nephrology and Clinical Chemistry), University of Tuebingen, Otfried-Muellerstrasse 10, 72076 Tuebingen, Germany. Electronic address:
Thyrotropin-releasing hormone (TRH) causes a variety of thyroidal and non-thyroidal effects, the best known being the feedback regulation of thyroid hormone levels. This was employed in the TRH stimulation test, which is currently little used. The role of TRH as a cancer biomarker is minor, but exaggerated responses to TSH and prolactin levels in breast cancer led to the hypothesis of a potential role for TRH in the pathogenesis of this disease.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!